Drug Review: Daridorexant

International Journal of Pharmacology and Clinical Sciences, 2023, 12, 2, 90-91.
DOI: 10.5530/ijpcs.2023.12.11
Published: September 2023
Type: Research Article
Authors: Juman Alsaab

Author(s) affiliations:
Juman Alsaab, Pharm D 
Ministry of Health, Riyadh, SAUDI ARABIA.


Registrations: had been registered in the following countries United States of America (USA), United Kingdom (U.K.), Canada, and Saudi Arabia (SA). Trade name (USA.); QUVIVIQ® Registration number (S.A.); Not Available. Insurance Drug Formulary (S.A.); Not covered (28.1.2023). General Information: Registered Company: Idorsia Pharmaceuticals, Ltd. Regulatory Status: R.X. Mechanism of Action: The treatment of insomnia is presumed to be through the antagonism of orexin receptors. In addition, the orexin neuropeptide signaling system plays a role in wakefulness. Blocking the binding of wake-promoting neuropeptides orexin A and orexin B to receptors OX1R and OX2R is thought to suppress wake drive. Read more…